BIOLASE, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John R. Beaver
- Full Time Employees
- 157
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 27042 Towne Centre Drive Foothill Ranch CA United States of America 92610-2811
- IPO Date
- Nov 12, 1992
- CIK
- 0000811240
- Website
- biolase.com
- Similar Companies
- Business
- BIOLASE, Inc., along with its affiliated entities, designs, produces, markets, and distributes sophisticated laser solutions for dental professionals and their patients across both domestic and international markets. This medical device company specializes in systems that allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to execute a broad spectrum of minimally invasive procedures, spanning cosmetic enhancements, restorative treatments, and intricate surgical applications. The company's product offerings include the innovative Waterlase all-tissue dental laser platforms, adept at precisely working on both soft and hard tissues, and the Epic diode soft-tissue laser systems, utilized for procedures such as soft tissue modification, pain management, and teeth whitening. Consumables and accessories, like disposable tips, flexible fibers, handpieces, and whitening gel kits, also form a part of its product portfolio. These systems aim to provide benefits such as reduced pain, less need for anesthesia, quicker recovery, and enhanced patient comfort. Headquartered in Foothill Ranch, California, and founded in 1984, BIOLASE has established itself as a global leader in dental laser technology. In late 2024, the company underwent a significant strategic shift, filing for Chapter 11 bankruptcy in October 2024 and subsequently being acquired by MegaGen Implant Co., LTD in November 2024 through an auction process. This acquisition positions BIOLASE as a MegaGen company, uniting laser and implant technologies to further advance clinical outcomes in dentistry. Previously delisted from Nasdaq in June 2024, the company's shares now trade on the OTC Pink Market. BIOLASE continues its commitment to innovation, holding numerous active patents for its laser technologies.
MegaGen and BIOLASE Invest Nearly $1 Million to Expand Manufacturing Infrastructure at Corona, California Facility
BIOLASE Showcases Advanced YSGG Laser Solutions for Periodontal and Implant Care at GNYDM 2025
BIOLASE Showcases Breakthrough YSGG Laser Protocol for Predictable Periodontitis Treatment at AAP 2025
BIOLASE Emerges Stronger Than Ever Under New Ownership by MegaGen Implant
BIOLASE Voluntarily Initiates Chapter 11 Proceedings
BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen
BIOLASE Announces Delisting from Nasdaq
BIOLASE, Inc. (BIOL) Q1 2024 Earnings Call Transcript
Biolase Reports 2024 First Quarter Results; Reiterates Full-Year 2024 Guidance For Revenue Growth and Profitability
BIOLASE to Report First Quarter 2024 Results on May 13, 2024
BIOLASE, Inc. (BIOL) Q4 2023 Earnings Call Transcript
Biolase Reports Full-Year 2023 Results; Expects Continued Revenue Growth In 2024
BIOLASE to Report Fourth Quarter and Full Year 2023 Results on March 21, 2024
Biolase Launches State-of-the-Art All-Tissue Laser System To Accelerate Adoption of Lasers in Dentistry
Biolase Announces First Quarter 2024 Webinar Series 'Lets Talk Dental'
BIOLASE, Inc. Announces Closing of $7.0 Million Public Offering
BIOLASE, Inc. Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement
BIOLASE, Inc. Announces Pricing of $7.0 Million Public Offering
Top 5 Health Care Stocks That Are Preparing To Pump In February - CNS Pharma (NASDAQ:CNSP), Biolase (NASDAQ:BIOL)
BIOLASE REPORTS UNAUDITED REVENUE GROWTH FOR FULL YEAR 2023 AND PROVIDES OUTLOOK FOR FULL YEAR 2024